Adams STH_2008.pdf (107.47 kB)
Novel Considerations in the Pathogenesis of the Antiphospholipid Syndrome: Involvement of the Tissue Factor Pathway of Blood Coagulation
journal contribution
posted on 2023-05-16, 21:52 authored by Adams, MJThe antiphospholipid syndrome (APS) is characterized by clinical manifestations such as venous and arterial thrombosis, thrombocytopenia and/or recurrent pregnancy loss, as well as the persistent presence of laboratory markers of antiphospholipid (aPL) antibodies detected in laboratory assays. Though it is generally accepted that aPL antibodies, such as anticardiolipin (aCL), anti-beta2 glycoprotein I (anti-beta2GPI), and lupus anticoagulants (LA) contribute to the pathogenesis of APS, precise mechanism(s) are yet to be fully described. It is probable that aPL antibodies bind to a range of cellular targets (e.g., platelets, endothelial cells, and monocytes), leading to thrombosis and obstetric complications. There is now increasing evidence that alterations to the tissue factor (TF) pathway of blood coagulation contribute toward hypercoagulability in patients with aPL antibodies. This article reviews current evidence that suggests changes and/or interference to the major pathway of blood coagulation may represent a novel mechanism that contributes to the development of APS.
History
Publication title
Seminars in Thrombosis and HemostasisVolume
34Pagination
251-255ISSN
0094-6176Department/School
School of Health SciencesPublisher
Thieme Medical PublishingPlace of publication
New York, USARepository Status
- Open